在这项研究中，基于大规模蛋白组学的蛋白质风险评分在临床风险因素模型的基础上略为提升了对动脉粥样硬化性心血管疾病（ASCVD）的区分能力。详情请见链接：https://ja.ma/44iFQW7。 #蛋白质风险评分 #ASCVD #医学研究 🔗抱歉，我没有能力打开您提供的链接，也无法浏览链接内容。请提供更多详细的信息或详述您的问题，以便我可以帮助您。

RT @SABOURETCardio
I’m still surprised by the high number of #LLT #statins deniers despite the amount of proofs. But we still try to support a better management of #ASCVD patients despite toxic people. “Ignorance is mother of arrogance “ despite Easter

Great intro to @SVM_tweets by @herbaronowMD at the #23FellowsAPP course.

#VascularMedicine so important to #ASCVD management.

@APAC_Cardiology #PhysicianAssociate #HeartPA

Here, reppin’ @APAC_Cardiology at @SVM_tweets APP course in #ATL.

#PAD is the oft forgotten 3rd leg of #ASCVD

🦵🏾PAD = higher ASCVD events than those w/prior MI/CVA
🦵🏾Early dx and intensive tx = ⬇️MACE/MALE
🦵🏾👀 for it, use ABI!

#PAD - the forgotten #ASCVD component.

🦵🏾MI/CVA events higher in PAD than in prior MI/CVA pts!!!!
🦵🏾Low use of statins/other LLT in PAD 👀😮
🦵🏾#LLT effective in PAD: statinize!

#acc23